Brief: Additional Data from Hepion Pharmaceuticals' Phase 2a Trial Further Strengthens CRV431 Clinical Profile
13/09/2021 14:23
Sept 13 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* ADDITIONAL DATA FROM HEPION PHARMACEUTICALS’ PHASE 2A
‘AMBITION’
TRIAL FURTHER STRENGTHENS CRV431 CLINICAL PROFILE AND PAVES WAY
FOR INITIATION OF PHASE 2B ‘ASCEND-NASH’ CLINICAL PROGRAM
* HEPION PHARMACEUTICALS INC - PRO-C3 AND ALT REDUCTIONS
POINT TO
ANTI-INFLAMMATORY AND ANTIFIBROTIC EFFECTS OF CRV431
* HEPION PHARMACEUTICALS INC - PK-PD MODELS SUCCESSFULLY
PREDICT
EARLY REDUCTIONS IN PRO-C3 AND ALT
Source text for Eikon: ID:nGNX5RCv6F
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement